SUMMARY The sera of 74 individuals with chronic lymphoproliferative disease were screened for the presence of inhibitory activity against neutrophil chemotaxis. This was present in more than half the patients with IgA myeloma and Hodgkin's disease but was less common in chronic lymphocytic leukaemia, lymphocytic lymphoma and non-IgA paraproteinaemia. Heating the sera prior to testing frequently enhanced inhibitory activity particularly in myeloma and lymphoma.
It is well known that people with chronic lymphoproliferative disease (LPD) may have significant impairment of host defence mechanisms including that of impaired acute inflammatory response. Subjects with multiple myelomatosis (MM),' chronic lymphocytic leukaemia (CLL),2 lymphocytic lymphoma (LL),3 and Hodgkin's disease (HD),4 have been reported to have increased susceptibility to infections. Granulocyte dysfunction may contribute to this problem especially if induced by extracellular factors associated with the underlying disorders.
The following mechanisms may be considered:
Neutropenia as a result of "marrow failure" may occur consequent upon replacement of the marrow by tumour, suppression by tumour products, or damage by the myelotoxic effects of chemotherapy.
Immunoglobulin (Ig) deficiency is particularly seen in MM and CLL. It is one of the diagnostic criteria for the former, and is present in at least half of the patients with the latter..5 6Whatever the cause,78 the resultant lack of Ig, especially of IgG, leads to [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] We have undertaken a search for such inhibitors using a suitable method for screening as we have recently described.22 Some characteristics of these substances have also been noted.
Material and methods
Seventy-four patients with lymphoproliferative disease attending the Southampton group of hospitals and 13 normals were tested for the presence in their serum of inhibitory material which would impair the migration of normal neutrophils towards a chemotactic mixture (normal pooled serum). As far as possible an aliquot of serum taken before treatment was tested, but sometimes it was necessary to test patients' sera during the intervals between therapy.
POOLED AB SERUM (PABS)
This was prepared from pools of three or more donors of AB blood group, and was used as the standard chemotaxin. The pools were all pretested to ensure that they produced a "leading front"2' (ie the distance moved by the fastest 2 cells) of at least 100 ,m when used at a 10% dilution in Hanks' basal salt solution with 0-2% human serum albumin added (HBSS-HSA).
INDICATOR CELLS
These were obtained from a small panel of volunteer staff donors who were of blood group 0. Twenty millilitres of blood was added to 100 I.U. heparin and then dextran-sedimented. The leucocytes were washed twice and resuspended in HBSS-HSA to give a concentration of about 4 x 109 leucocytes/l.
The details of the apparatus and methods have been described elsewhere.22 Our development of the Addison and Babbage raft modification23 of Boyden's chamber24 permitted us to screen up to 15 sera simultaneously ensuring maximal similarity of experimental conditions.
We had previously described an assessment of chemotaxis based on the percentage cumulative sum of migrating cells at five different levels into a 3 am membrane (see Fig. 1 ). However, this series of patients included some with extremely strong inhibition of chemotaxis and a curve instead of a straight line was obtained when cell number was plotted against distance moved. By plotting the natural logarithmic value of x (lnx), a straight line was obtained, and the gradient was easier to visualise and measure. We therefore used the formula y = m (1nx) + c, rather than y = m x + c where y =% Jayaswal, Roper, Roath cumulative sum of migrating cells; x = depth (,m) into membrane where cells were counted; c = constant; m = the gradient of the line that was best fit for the set of points available. Fig. 2 shows the correlation of the m values from both these assessments. (31) HD (11) 0 28% (5) 47% (7) 29% (9) 64% (7) room temperature for half an hour. The mixture was then made up to 1 ml with HBSS-HSA. This represented a final concentration of 10% PABS and 10% test serum. The rest of the chemotaxis plate was similarly made up with other sera to be screened in the manner of steps (iii) and (iv). It was usual to screen 10 sera but up to 15 was possible; each serum was tested in duplicate.
If a serum was shown on screening to have inhibitory activity, the test was repeated to see if the activity was affected by heating (56°C for 30 min) or by overnight dialysis (at 4°C with phosphatebuffered saline at pH 7.2).
Results Figure 1 illustrates how the migration curve of the semilogarithmic plot was altered from the curve to a straight line using the natural logarithm of x. Figure  2 shows that the gradients derived from each plot correlated well with each other and conclusions were interchangeable providing comparisons were made in kind-that is, the gradients from the linear plot should not be compared with those from the logarithmic plot. = loss or reduction of inhibitory activity.
T = emergence or enhancement of inhibitory activity.
as described for 11 pools of AB serum estimated on a total of 42 occasions at 10% and 41 occasions at 20% dilution in HBSS-HSA. Table 2 gives the similarly calculated values of m for normal control sera. This was used as a basis for comparing test sera (10%) under study. We chose a 15% (one SD) or more reduction as suggestive of the need for further study of the serum. The results were obtained from experiments separately performed in order to obtain the range for normal people. Table 3 gives the results observed in the normal population ("well" subjects) and the four disease groups. The m values of the preincubated mixtures of PABS and test sera were compared with the m value of PABS 10% for that day. The rationale used was that: if the test sera was "inert" as far as chemotaxis was concerned then the chemotactic effect of the mixture would remain the same as that of the 10% PABS positive control and if there was an enhancement (which might be expected, due to increased serum content) it would not be significant unless greatly different from the 20% PABS positive control for the day; however, if an inhlibitor activity was present the stimulant effect of PABS would be reduced. Again a greater than 15% inhibition was considered an indication to retest the serum. Table 4 shows the analysis of paraproteinaemic sera by their Ig groups. IgM is not associated with inhibitory activity in any of our cases.
Finally, Table 5 shows the results of the partial characterisation studies performed on some of the test sera. (Not all the positive sera could be retested because some stored aliquots were insufficient for these procedures.) Discussion Significant inhibitory activity was not observed in normal sera; none was induced by storage, dialysis, nor by heating of aliquots used for preincubated mixtures. Sera from 7/15 myeloma patients were inhibitory, this effect increasing after storage, or after heating. Heated, stored sera were the most inhibitory.
In other groups of patients, storage seemed to cause a loss of inhibitory activity. This, however, could be restored by heating, particularly in those sera from the lymphoma group. Thus it would seem that in these patients there may be two 
